China Biotech Services Holdings Limited

As of June 30, 2024, China Biotech Services Holdings Limited carries a market capitalization of 382.48M, placing it among publicly traded companies globally. Its enterprise value stands at 507.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, China Biotech Services Holdings Limited has 956.19M shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, China Biotech Services Holdings Limited maintains a current ratio of 0.74, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, China Biotech Services Holdings Limited recorded an income tax benefit of -5.14M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, China Biotech Services Holdings Limited's stock has declined approximately 45.65% over the past 52 weeks. The 50-day moving average sits at 0.58, while the 200-day moving average is 0.66.

As of June 30, 2024, China Biotech Services Holdings Limited holds 33.24M in cash and equivalents against 166.86M in total debt, resulting in a net debt position of 121.85M. Total book value stands at 390.22M, with working capital of -54.42M providing operational flexibility.

China Biotech Services Holdings Limited's most recent stock split took place on March 8, 2016 with a 2:1 split ratio.